3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
5
Endometrial Neoplasms
5
Neoplasms
4
Head and Neck Neoplasms
3
Breast Neoplasms
3
Rectal Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Ovarian Carcinosarcoma
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lung Neoplasms
1
Laryngeal Diseases
1
Hemangiosarcoma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
Interventions
Bevacizumab
35
Paclitaxel
31
Carboplatin
24
pembrolizumab
23
Specimen Handling
21
Magnetic Resonance Spectroscopy
19
Gemcitabine
18
olaparib
16
liposomal doxorubicin
16
Cyclophosphamide
15
fludarabine
12
Topotecan
12
Biopsy
12
niraparib
11
Cisplatin
10
Taxes
8
Nivolumab
8
Immunoglobulin G
8
Fulvestrant
8
Disulfides
8
Doxorubicin
7
aldesleukin
6
Surveys and Questionnaires
6
palbociclib
5
Oxaliplatin
5
Fluorouracil
5
trastuzumab deruxtecan
4
oregovomab
4
mirvetuximab soravtansine
4
X-Rays
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
dostarlimab
×
90 days
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled